Members in attendance
Al Heaton, RPh, Stuart Williams, J.D., Eric Meininger, M.D., Michael Sprehe, M.D., James Phillips, M.D., Stacey Ness, Pharm.D, Margaret Artz, RPh, Ph.D., Monica Brands, R.Ph.

Members absent:
Kelly Ruby, Pharm.D; Kathryn Lombardo, M.D.

DHS staff present
Sara Drake, RPh., MPH, MBA, Dave Hoang, Pharm.D., MBA

Others in attendance
Nina Bandali, Pharm.D.

Announcements
DFC recognized outgoing physician member, Dr. William Korchik, for his outstanding contribution to the DFC throughout the years.

DFC welcomed new physician member, Dr. Eric Meininger.

Sara Drake announced her departure from DHS effective January 6, 2017

Report of the Chair
No updates

Approval of the minutes
Minutes from the August 23, 2016 meetings was reviewed and approved

Old Business

Orkambi Update
The committee was provided an update on Orkambi PA criteria. The committee discussed and recommended to the department by a unanimous vote to remove (a) the PA requirement of patient’s participation in the CF Patient Registry maintained by the CF Foundation; and (b) the CF Questionnaire-Revised (CFQ-R) respiratory domain score from the renewal criteria

New Business

Update on MN Policy on Synagis for 2016-2017 Season
The committee was provided an update on MN policy on Synagis for 2016-2017 Season.

New Specialty Drugs for Continued PA
The committee discussed Taltz (Lilly) and recommended to the department that Taltz remain on PA by a unanimous vote.
The committee discussed Cinqair (Teva) and recommended to the department by a unanimous vote that Cinqair remain on PA. The committee also recommended to the department by a unanimous vote that Cinqair be re-evaluated in one year.

The committee discussed Venclaxta (AbbVie) and recommended to the department by a unanimous vote that Venclexta remain on PA.

The committee discussed Carbometyox (Exelixis) and recommended to the department by a unanimous vote that Carbometyox remain on PA.

The committee discussed Zinbryta (AbbVie) and recommended to the department by a unanimous vote that Zinbryta remain on PA.

The committee discussed Ocaliva (Intercept) and recommended to the department by a unanimous vote that Ocaliva remain on PA. The committee also recommended to the department by a unanimous vote that Ocaliva be only approved for FDA-approved indication and NASH is not an FDA-approved indication.

The committee discussed Probuphine (Braeburn) and recommended to the department by a unanimous vote that Probuphine remain on PA using existing criteria and that Probuphine-specific PA criteria will be discussed at a future meeting.

The committee discussed Zurampic (AstraZeneca) and recommended to the department by a unanimous vote that Zurampic remain on PA.

**New Drugs for Continued PA**

The committee discussed Vraylar (Allergan) and recommended to the department by a unanimous vote that Vraylar remain on PA. The committee also recommended to the department by a unanimous vote that the PA criteria include a step therapy edit to include a trial and failure of Abilify and one other preferred atypical antipsychotic.

The committee discussed Nuplazid (Acadia) and recommended to the department by a unanimous vote that Nuplazid remain on PA.

The committee discussed Briviact (Shire) and recommended to the department by a unanimous vote that Briviact remain on PA.

The committee discussed Xiidra (Acadia) and recommended to the department by a unanimous vote that Xiidra remain on PA.

**Specialty Product List Review**

The committee reviewed specialty product list of categories and recommended to the department by a unanimous vote that newly approved/introduced specialty products that fall into one of the following categories be considered specialty until further review and recommendation by the committee:

- Hemophilia - Hemostatics -
- Blood Cell Deficiency - Anemia - RBC growth factors (ESAs)
- Blood Cell Deficiency - Neutropenia - White cell growth factors (G-CSFs)
- Biologic Response Modifiers (e.g. Actimmune, Revlimid)
- Cancer - Antineoplastic Agents
• Cystic Fibrosis (e.g. Pulmozyme, TOBI)
• Cancer, other – Xgeva, Zometa
• Lysosomal Storage Ds Therapies
• Hereditary Angioedema - Complement Inhibitors
• Primary Immune Deficiencies - IVIG -Immune Globulin (IgG) - Serums
• Multiple Sclerosis - Biologic Response Modifiers (BRMs) (e.g. Avonex, Copaxone, Rebif)
• Pulmonary Arterial Hypertension (PAH)
• Rheumatoid Arthritis/Psoriasis/Crohn's -TNF Blockers - BRMs
• HIV/AIDS - Antiviral
• Hepatitis B or C - Antiviral

Adjournment
The meeting was adjourned at 8:45 pm Central Time.